The National Institute for Health and Care Excellence recommended that three drugs for treatment of blood cancer be made available on the U.K.’s National Health Service.
Two of the drugs, midostaurin and arsenic trioxide, are recommended for adults with certain forms of leukemia. The third, brentuximab vedotin, was previously only available through the Cancer Drugs Fund.
The drugs will be available to any eligible patients three months after NICE publishes its final guidance. Midostaurin and brentuximab vedotin will be available at a confidential discounted price.